NikhilIshwarKhushalaniMD

Hematologic Oncology, Melanoma

Senior Member (Tenured), Moffitt Cancer Center

Overview of Dr. Khushalani

Dr. Nikhil Khushalani is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Topiwala National Medical College and has been in practice 22 years. Dr. Khushalani accepts several types of health insurance, listed below. He is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
Moffitt Cancer Center, Division of Cutaneous Oncology
10920 N. McKinley Drive
Tampa, FL 33612
Book by Phone+1(484) 929-2974

Fax+1 813-449-8584

Education & Training

University at BuffaloFellowship, Hematology and Medical Oncology, 1999 - 2002
University at BuffaloResidency, Internal Medicine, 1996 - 1999
Topiwala National Medical CollegeClass of 1995

Certifications & Licensure

FL State Medical License 2015 - 2026
NY State Medical License 2006 - 2016
American Board of Internal Medicine Medical Oncology

Clinical Trials

Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer Start of enrollment: 2006 Nov 01
Completed
Phase 2
Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer Start of enrollment: 2007 May 01
Terminated
Phase 1
Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer Start of enrollment: 2006 Nov 01
Completed
Phase 1
Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2008 May 01
Terminated
Phase 2
Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer Start of enrollment: 2009 Dec 01
Withdrawn
Not Applicable
Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer Start of enrollment: 2010 Sep 01
Completed
Phase 2
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2011 Jan 18
Completed
Phase 2
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery Start of enrollment: 2012 Jan 01
Terminated
Phase 2
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Start of enrollment: 2013 Jul 01
Terminated
Phase 1, Phase 2
Randomized Phase II Study of AB (Abraxane™, Bevacizumab) Versus Ipilimumab for 1st Line Therapy of Unresectable Stage IV Metastatic Malignant Melanoma (BRAF V600E Negative) Start of enrollment: 2013 Oct 01
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2013 Oct 18
Completed
Phase 2
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Start of enrollment: 2014 Jul 11
Active, not recruiting
Phase 2, Phase 3
Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer Start of enrollment: 2016 Aug 01
Completed
Phase 1, Phase 2
Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma Start of enrollment: 2019 May 14
Completed
Phase 2
Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study Start of enrollment: 2020 Jan 30
Withdrawn
Early Phase 1
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Start of enrollment: 2023 Oct 31
Recruiting
Phase 2, Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

496 citations
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B. Johnson, Ryan J. Sullivan, Patrick A. Ott, Matteo S. Carlino, Nikhil I. Khushalani
JAMA Oncology. 2016-02-01
129 citations
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
Amod A. Sarnaik, Omid Hamid, Nikhil I. Khushalani, Karl D. Lewis, Theresa Medina
Journal of Clinical Oncology. 2021-05-12
70 citations
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immu...
Jason Chesney, Karl D Lewis, Harriet Kluger, Omid Hamid, Eric Whitman
Journal for Immunotherapy of Cancer. 2022-12-01

Journal Articles

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Kim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
Jade Homsi, Michael R Migden, Nikhil I Khushalani, The New England Journal of Medicine
Malignant Adnexal Tumors of the Skin: A Single Institution Experience
Valerie Francescutti, Kilian Salerno, John 3rd Kane, Tolutope Oyasiji, Joseph Skitzki, Nikhil I Khushalani, BioMed Central

Lectures

CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously un...
2019 ASCO Annual Meeting - 6/1/2019
Melanoma 2013: Standard Treatment, Novel Therapies, and Ongoing Controversies
Cvent Online Event Registration Software, Amherst, New York - 4/13/2013
13th Annual Radiation Oncology Conference for Therapists & Dosimetrists
Roswell Park Cancer Institute, Niagara Falls, New York - 9/6/2012

Press Mentions

Moffitt's 'Mole Patrol' Offers Free Skin Cancer ScreeningsMay 1st, 2022
Rationale for Combining a Modified IL-2 and Nivolumab in MelanomaJuly 8th, 2019
Immunotherapy Combo Fails Melanoma TestJune 26th, 2019
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
GHI PPO
Great West PPO
HealthAmerica HealthAssurance PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Medical Mutual of Ohio SuperMed Plus
Medical Mutual of Ohio SuperMed POS
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare HMO
MVP Healthcare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment